Neutrophil-to-lymphocyte ratio in COPD flare-ups.
Neutrophil to Lymphocyte Ratio in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Marker of Severity and Prognosis
This project will test whether a routine blood measure called the neutrophil-to-lymphocyte ratio can help predict severity, outcomes, and treatment response in adults hospitalized with COPD flare-ups.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 190 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ain Shams University Academic / other |
| Locations | 1 site (Cairo, Abbasyea) |
| Trial ID | NCT07125352 on ClinicalTrials.gov |
What this trial studies
This is a single-center observational study enrolling adults hospitalized with acute exacerbations of COPD at the Chest Department of Ain Shams University Hospitals. Researchers will calculate the neutrophil-to-lymphocyte ratio (NLR) from routine blood counts and correlate NLR values with measures of clinical severity, adverse outcomes, and response to treatment. Patients with malignancy or hematological disorders are excluded to avoid confounding of blood counts. The study aims to determine whether NLR, an inexpensive inflammatory marker, adds prognostic information in the hospital setting.
Who should consider this trial
Good fit: Adults aged 18 and above admitted to the Chest Department at Ain Shams University with an acute COPD exacerbation defined by GOLD 2024 criteria are ideal candidates.
Not a fit: Patients with active cancer or hematologic disorders, outpatients with stable COPD, or those who refuse treatment are unlikely to benefit because their NLR may be confounded or they are not hospitalized.
Why it matters
Potential benefit: If successful, measuring NLR could help doctors spot patients at higher risk during COPD flare-ups and make treatment decisions sooner.
How similar studies have performed: Previous studies have reported mixed results—some have linked higher NLR to worse outcomes in COPD and pneumonia, but findings remain inconsistent and debated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 and above, Patients who will be admitted at the Chest department, Ain-Shams University Hospitals, diagnosed with AECOPD based on the Global Initiative for Chronic Obstructive Lung Disease 2024 criteria Exclusion Criteria: * Patients who refused treatment. * COPD patients with Malignancy, hematological disorders
Where this trial is running
Cairo, Abbasyea
- Ain Shams University — Cairo, Abbasyea, Egypt (Recruiting)
Study contacts
- Study coordinator: Hieba G Ezzelregal, MD
- Email: hiebagamal24@med.asu.edu.eg
- Phone: 01002041611
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.